An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

NCT02557646 · clinicaltrials.gov ↗

COMPLETED

Status

697

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

BIOLOGICAL: Peginterferon alfa-2a
DRUG: Ribavirin

Sponsor

Hoffmann-La Roche